Vera Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Vera Therapeutics, Inc. (VERA) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $15.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-10
- Vera Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $15.86M, a 67.47% increase year-over-year.
- Vera Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $13.21M, a 70.56% increase year-over-year.
- Vera Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $9.74M, a 74.39% increase year-over-year.
- Vera Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $9.47M, a 94.38% increase year-over-year.
- Vera Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $37.93M, a 82.32% increase from fiscal 2024.
- Vera Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $20.80M, a 81.00% increase from fiscal 2023.
- Vera Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $11.49M, a 29.32% increase from fiscal 2022.
- Vera Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $8.89M, a 195.05% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.86M 10-Q · filed 2026-08-10 | $29.07M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $13.21M 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $37.93M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $9.74M 10-Q · filed 2025-11-05 | $19.22M derived: sum of 2 quarters · filed 2026-08-10 | $26.96M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-06-30 | $9.47M 10-Q · filed 2026-08-10 | $17.22M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $7.74M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $20.80M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $5.59M 10-Q · filed 2025-11-05 | $10.46M derived: sum of 2 quarters · filed 2025-11-05 | $14.59M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $4.87M 10-Q · filed 2025-11-05 | $9.00M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $4.12M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $11.49M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | $2.92M 10-Q · filed 2024-11-07 | $5.61M derived: sum of 2 quarters · filed 2024-11-07 | $8.27M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $2.68M 10-Q · filed 2024-11-07 | $5.35M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $2.67M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $8.89M 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $2.45M 10-Q · filed 2023-11-09 | $4.48M derived: sum of 2 quarters · filed 2023-11-09 | $6.14M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $2.02M 10-Q · filed 2023-11-09 | $3.69M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $1.66M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $3.01M 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $933.00K 10-Q · filed 2022-11-09 | $1.65M derived: sum of 2 quarters · filed 2022-11-09 | $2.05M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $713.00K 10-Q · filed 2022-11-09 | $1.12M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $404.00K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $331.00K 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $55.00K 10-Q · filed 2021-11-10 | $127.00K derived: sum of 2 quarters · filed 2021-11-10 | $188.00K derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $72.00K 10-Q · filed 2021-11-10 | $72.00K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $61.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |